Abstract:Ethnopharmacological relevance: The Chinese formula Guben-Jiannao Ye (GBJNY) formula has a long history of usage in traditional Chinese medicine (TCM) for the treatment of learning and memory disorders as well as senile insomnia. This formulation is derived from Sun Simiao's five tonic pills. Furthermore, modern pharmacological investigations have revealed its ability to improve cognitive impairment and ameliorate sleep-wake circadian rhythm disorders. However, the precise mechanism underlying its efficacy remains elusive. Aim of the study: The current research explored the modulatory effects and possible mechanisms of GBJNY in circadian rhythm sleep-wake disorders and cognitive dysfunction in Alzheimer's disease using transcriptome sequencing and experimental validation. Materials and methods: The LC-MS/MS tandem technology was utilized to qualitatively discern the active components present in GBJNY. The APP/PS1 mice received continuous treatment with GBJNY or Melatonin for 3 months. The learning and memory abilities of mice were assessed utilizing the Morris water maze (MWM) test, while sleep changes were studied utilizing the electroencephalogram (EEG) and electromyogram (EMG). Concurrently, mice's hippocampus clock gene rhythmicity was investigated. Subsequently, we employed HE staining, Golgi staining, and immunofluorescence to observe GBJNY's impact on synaptic damage and neuronal loss. We performed high-throughput sequencing to analyze the mRNA expression profiles of mice, aiming to identify differentially expressed genes (DEGs). Subsequently, we conducted GO and KEGG enrichment analyses to explore associated signaling pathways. Furthermore, we evaluated the expression levels of proteins involved in the PI3K/AKT/mTOR pathway and Aβ deposition in the hippocampus of mice. Through this comprehensive approach, we sought to elucidate and validate the potential mechanisms of action of GBJNY in APP/PS1 mice. Results: Results showed 216 DEGs. Following this, we conducted GO enrichment and KEGG pathway analyses to delve deeper into the distinctions and fundamental functions of the mRNA target genes. The enrichment analysis underscored the prominence of the PI3K/Akt/mTOR signaling pathway as the most pivotal among them. Through in vivo experiments, it was further demonstrated that the administration of GBJNY enhanced memory and learning capacities in APP/PS1 mice. Additionally, GBJNY treatment resulted in alterations in the sleep-wake circadian rhythm, characterized by reduced wakefulness and an increase in non-rapid eye movement (NREM) sleep. Moreover, alterations in the peak expression of Per1, Per2, Clock, Cry1, Cry2, and Bmal1 mRNA were noted in the hippocampus of treated mice. Particularly noteworthy were the observed reductions in amyloid-beta (Aβ) deposition within the hippocampus, improvements in neuronal synaptic integrity, and upregulation of mTOR, Akt, and PI3K protein expression in the hippocampal region. These findings underscore the critical involvement of the PI3K/Akt/mTOR signaling pathway in mitigating disturbances in sleep-wake circadian rhythms. Conclusions: GBJNY enhanced the cognitive performance of APP/PS1 mice and altered clock gene expression patterns, alleviating sleep-wake circadian rhythm disruptions. The fundamental mechanism appears to be linked to the PI3K/Akt/mTOR pathway regulation, offering a foundation for potential clinical applications.

Tenuigenin promotes non-rapid eye movement sleep via the GABA A receptor and exerts somnogenic effect in a MPTP mouse model of Parkinson's disease

Tenuifolin, a Saponin Derived from Radix Polygalae, Exhibits Sleep-Enhancing Effects in Mice

Tenuifolin ameliorates the sleep deprivation‐induced cognitive deficits

Effects of Tenuifolin on Rest/wake Behaviour in Zebrafish

Trihexyphenidyl increases delta activity in non-rapid eye movement sleep without impairing cognitive function in rodent models

Neuroprotective and Neurogenic Effects of Novel Tetramethylpyrazine Derivative T-006 in Parkinson's Disease Models Through Activating the MEF2-PGC1α and BDNF/CREB Pathways

Ginsenoside Rg5/Rk1 ameliorated sleep via regulating the GABAergic/serotoninergic signaling pathway in a rodent model

0258 Altered sleep regulation in a mouse model of Parkinson’s disease

Ginsenoside Rg5/Rk1 ameliorated sleep <i>via</i> regulating the GABAergic/serotoninergic signaling pathway in a rodent model

Study on the hypnotic effect of rare protopanaxadiol-type and protopanaxatriol-type ginsenosides

Ginsenoside Rg1 Promotes Sleep in Rats by Modulating the Noradrenergic System in the Locus Coeruleus and Serotonergic System in the Dorsal Raphe Nucleus

Tetramethylpyrazine nitrone exerts neuroprotection via activation of PGC-1α/Nrf2 pathway in Parkinson’s disease models

Objective sleep enhancement in Parkinson's disease: A sham-controlled trial of low-frequency repetitive transcranial magnetic stimulation over the right dorsolateral prefrontal cortex

Neuroprotective Effects of Tenuigenin in a SH-SY5Y Cell Model with 6-Ohda-induced Injury

L-theanine and Neumentix Mixture Improves Sleep Quality and Modulates Brain Neurotransmitter Levels in Mice.

Ginsenoside Rg1 promotes non-rapid eye movement sleep via inhibition of orexin neurons of the lateral hypothalamus and corticotropin-releasing hormone neurons of the paraventricular hypothalamic nucleus

Ginsenoside Rb1 Ameliorates Working Memory Deficits Via Regulation of Prefrontal Cortical Gabaergic Transmission in MPTP-Treated Mice

Chinese formula Guben-Jiannao Ye alleviates the dysfunction of circadian and sleep rhythms in APP/PS1 mice implicated in activation of the PI3K/AKT/mTOR signaling pathway

GABA Transporter-1 Inhibitor NO-711 Alters the EEG Power Spectra and Enhances Non-Rapid Eye Movement Sleep During the Active Phase in Mice.

Objective Sleep Enhancement in Parkinson’s Disease: a Sham-Controlled Trial of Low-Frequency Repetitive Transcranial Magnetic Stimulation over the Right Dorsolateral Prefrontal Cortex

GABAergic neurons in the rostromedial tegmental nucleus are essential for rapid eye movement sleep suppression